[Therapeutics of Burkitt lymphoma in adults - review].

Abstract

Burkitt lymphoma is a highly aggressive non-Hodgkin's lymphoma. As Burkitt lymphoma cells are very sensitive to chemotherapy, chemotherapy is the major therapeutic schedule for this disease. Rituximab raised the overall survival rate markedly. Bone marrow transplant, surgery and radiotherapy also demonstrated to have a supporting role for patients with Burkitt lymphoma. This review focus on research progress of the therapeutics and major regimens for the disease.

• Authors: Li Li, Bao-An Chen
• Journal: Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 20 Issue 5 Pg. 1289-92 (Oct 2012) ISSN: 1009-2137 [Print] China
• PMID: 23114166 (Publication Type: English Abstract, Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Review)

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Rituximab

Topics

• Adult
• Antibodies, Monoclonal, Murine-Derived (therapeutic use)
• Bone Marrow Transplantation
• Burkitt Lymphoma (radiotherapy, surgery, therapy)
• Humans
• Rituximab